Exact Sciences’ Cologuard has been used in more than one million screenings for colorectal cancer, the company announced today.

“Approximately half of Cologuard users haven’t been screened before, and we’re excited that healthcare professionals and patients around the country are making Cologuard their noninvasive screening test of choice,” Exact Sciences CEO Kevin Conroy said in a statement.

According to a release, Cologuard is one of the most quickly adopted diagnostic technologies of all time, as this milestone comes less than four years after the test was approved by the FDA.

As previously reported, the Cologuard tests are processed in Exact Sciences’ Madison lab.